SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalABMD - Replacement Heart System


Previous 10 Next 10 
From: Lynn9/8/2018 3:36:43 PM
   of 147
 
What Analysts Expect for AbiomedMike Benson

Market Realist
September 5, 2018

Abiomed’s revenues As discussed earlier, Abiomed ( ABMD) reported revenues of $180.0 million in Q1 2019, a 36% increase as compared to revenues of ~$132.5 million in the first quarter of 2018.



The above graph compares the quarterly revenues of Abiomed since the first quarter of 2018.

Q1 2019 performance Abiomed’s top line increased ~35.9% to ~$180.0 million during Q1 2019. The increase was driven by a 37% increase in Impella heart pump sales globally to $173.7 million during Q1 2019 as compared to $127.2 million in the first quarter of 2018.

Impella heart pump sales The revenues for Impella heart pump in the US markets increased by ~32% to $151.7 million during Q1 2019 as compared to $114.7 million in the first quarter of 2018.

The revenues for Impella heart pump outside US markets increased by ~75% to $21.9 million during Q1 2019 as compared to $12.5 million during the first quarter of 2018.

Profitability during Q1 2019 Abiomed reported a decrease in gross profit margin to 82.9% during Q1 2019 as compared to a gross profit margin of 83.5% during the first quarter of 2018. The operating margin increased to 26.0% during Q1 2019 as compared to an operating margin of 25.0% during the first quarter of 2018.

The GAAP net income increased by ~141% to $90.1 million in Q1 2019 as compared to the GAAP net income of $37.4 million during the first quarter of 2018.

The iShares US Healthcare ETF ( IYH) holds 0.5% of its total investments in Abiomed ( ABMD), 1.3% in Boston Scientific ( BSX), 3.4% in Medtronic ( MDT), and 9.4% in Johnson & Johnson ( JNJ).



What Analysts Expect for AbiomedBy Mike Benson
Sep 5, 2018 | 1:20 PM

Wall Street analysts’ estimates Wall Street analysts estimate Abiomed ( ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018. The earnings per share are expected to be $4.66 in 2019. Analysts estimate the net income margin to increase to 27.3% during 2019 as compared to 18.9% during 2018.



The above chart compares changes in analysts’ recommendations for Abiomed since January 2018.

2019 guidance Abiomed estimates revenues to be between $755 million and $770 million during 2019, a 27% to 30% increase in revenues as compared to 2018. The operating margin is expected to be in the range of 28% to 30% in 2019.

Analyst ratings Abiomed’s stock price has increased by nearly 172.3% in the last 12 months and nearly 119.5% in 2018 year-to-date. Analysts estimate the stock might increase by 9.2% over the next 12 months. Wall Street analysts have a 12-month target price of $449.22 per share as compared to the last price of $411.36 per share as of September 4.

As of September 5, 11 analysts are tracking Abiomed. Of these, five analysts recommend a “strong buy,” four analysts recommend a “buy,” and two analysts recommend a “hold.” None of the analysts recommend a “sell.” The consensus rating for Abiomed stands at 1.73, which represents a “strong buy” for long-term growth investors as well as momentum investors. Changes in analysts’ estimates and recommendations are based on changing trends in stock prices and the performance of the company.

The iShares US Medical Devices ETF ( IHI) holds 2.3% of its total investments in Abiomed ( ABMD), 4.7% in Stryker ( SYK), 4.7% in Boston Scientific ( BSX), and 8.8% in Medtronic ( MDT).



finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Julius Wong9/9/2018 3:12:15 PM
   of 147
 
Analyst Ratings & Price Targets on Abiomed

tipranks.com

Share RecommendKeepReplyMark as Last Read


From: Lynn9/14/2018 9:13:20 PM
1 Recommendation   of 147
 
7 Tech Stocks Sporting Amazon-Like Growth

Louis Navellier
InvestorPlace
September 13, 2018

[Only ABMD section copied/pasted]

Tech Stocks to Buy: Abiomed, Inc. (ABMD)


View photos

Tech Stocks to Buy: Abiomed, Inc. (ABMD)

Abiomed, Inc. (NASDAQ: ABMD) makes specific medical devices that assist or replace the pumping function of a failing heart.

What makes ABMD’s devices unique is, implanting them is a relatively easy process, so significant costs or energy isn’t necessary up front.

For example, if someone comes into the Emergency Room with a heart attack, the team can put in an Impella Heart Pump and then, once the patient is stable, figure out what the next steps will be.

And its products are seeing very good results. In late October ABMD reported its FYQ2 numbers; revenue was up 29% and patient utilization was up by 33%.

Those are very big numbers and bode well for Impella’s future, especially because it packs a lot of bang for the buck, which makes health insurance companies very happy.

Up 104% YTD, ABMD is just starting its run.

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


To: High-Tech East who wrote (106)9/14/2018 11:47:16 PM
From: Lynn
   of 147
 
You haven't been around since 2005, Ken, hope you are fine. Looking back at past postings, this comment you made to Charles [when ABMD looked like it might be a candidate for Chapter 11] made me sigh:

... I am hanging in there indefinitely on Abiomed - I guess the same way lots of people are with Sun ...
SUNW... Talk about a climb into the stratosphere than about-face to the almost ground when ORCL snatched it--for cash rather than stock (groan). I still think about some people on that thread who could not believe it would continue to decline and actually bought more shares when it was in the 90s. Should ABMD start pulling a, "SUNW," I sure hope I am smart enough to bail! SUNW... I could cry. :(

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Lynn who wrote (136)9/24/2018 12:20:51 PM
From: dominoe
   of 147
 
Dont look now but we are soaring on positive news of our impact on lowering mortality and morbidity for certain cardiac ailment.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: Julius Wong9/24/2018 2:57:39 PM
1 Recommendation   of 147
 
Data Presented at TCT 2018 Shows Use of Impella and Best Practices Increases Cardiogenic Shock Survival

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


To: dominoe who wrote (137)9/24/2018 6:11:19 PM
From: Lynn
   of 147
 
Hey, thank you, dominoe. I have been a tad bit gloomy over a few stocks I recently (past 6 months) picked up. I needed this positive ABMD news/move!

Lynn

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Lynn who wrote (139)9/25/2018 12:07:17 PM
From: dominoe
   of 147
 
Then you must be feeling great between yesterday and today.
Go ABMD!

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: dominoe who wrote (140)9/25/2018 12:17:31 PM
From: Lynn
   of 147
 
:) :) Without looking how my make-me-groan stocks are doing, just reading your reply to me--which made my notebook 'ding,' seeing ABMD is up 6%--YES!! A ray of sunshine. Thanks, dominoe.

S&P 500 Movers: [worst performer removed], ABMDIn early trading on Tuesday, shares of ABIOMED (NASDAQ: ABMD) topped the list of the day's best performing components of the S&P 500 index, trading up 4.4%. Year to date, ABIOMED registers a 133.7% gain.

[snip to end]

marketnewsvideo.com

You are right, Go ABMD!!

Share RecommendKeepReplyMark as Last Read


From: Lynn9/28/2018 10:10:39 PM
   of 147
 
World's Smallest Heart Pump Fuels Red-Hot Medtech Stock By
Bailey Lipschultz

September 27, 2018, 7:30 AM EDT Updated on September 27, 2018, 10:37 AM EDT

Abiomed has more than doubled this year as revenue skyrockets

Patents and technology keep potential competitors at bay
It may be hard to justify buying a company that nearly tripled over the past 12 months, but then there’s Abiomed Inc.

With annual sales growth seen at more than 25 percent through 2021, the maker of the world’s smallest heart pump has quickened the pulse of investors, analysts and -- not surprisingly -- its chief executive.



Abiomed Impella

Source: Abiomed
“We’re just getting started,” Michael Minogue, president and CEO, said in an interview at the company’s headquarters earlier this month. Abiomed has spent more than $200 million over the last 10 years developing and improving its Impella devices, he said.

Abiomed’s hot run can be at least partially attributed to the patented technology that provides an almost impenetrable barrier from competitors seeking involvement in the segment. Plus, it has space in the market to grow. The Danvers, Massachusetts-based company estimates it has only reached about a tenth of its addressable market, with more products and patents on the horizon. On top of that, there’s global expansion.

Abiomed’s preparing for a rush. Its recently expanded facilities in Danvers and Aachen, Germany can now produce more than $1 billion in product a year. That compares to fiscal first quarter sales of $180 million, according to data compiled by Bloomberg.

The minimally invasive Impella devices can be inserted via a standard catherization procedure and allow patients to maintain their native heart instead of more invasive surgeries that may require a heart transplant. The tiny pump is slightly less than 5 millimeters in diameter compared to other devices that are more than double the size.



Of course, the rally that’s made it one of the Standard & Poor 500 Index’s hottest stocks this year may also give new investors pause. Shares opened higher on Thursday to extend what was an eight session rally, the longest winning streak in four years, before reversing gains.

Not a Bargain“If there’s one constraint on the company it is the valuation,” Jefferies analyst Raj Denhoy said in a phone interview. “It’s the most expensive stock that we track in medical devices and by a good amount, frankly. But again, it’d be hard to find another company with the characteristics as this company in terms of a sustainable growth story.”



Rapid adoption of Abiomed’s Impella technology, increased appreciation for the company’s competitive moats and pipeline optionality explain the company’s nearly two-year stock surge, according to BNP Paribas portfolio manager Jon Stephenson. And he sees more upside to come.

“A lot of people look at the valuation as mind-boggling, but in Abiomed’s case, the addressable market for the indications in which they’ve already launched are huge,” Stephenson, who helps oversee $450 million in BNP’s World Health Care fund, said by telephone. The company has 321 patents protecting its technology with an additional 338 pending, management noted.

Not to say that Abiomed’s completely protected from rivals. Abbott Laboratories’ HeartMate PHP is a device currently being studied to take on the Impella and its incarnations. That said, early results from a study underwhelmed analysts at the Transcatheter Cardiovascular Therapeutics meeting in San Diego over the weekend.

The updates showed Abiomed “will be without meaningful competition to Impella for several more years at least,” Jefferies’ Denhoy wrote in a note to clients. In the interim, there’s plenty of demand. The company has five approved pumps that qualify for reimbursement from the Centers for Medicare and Medicaid Services and major insurers, CEO Minogue said. The device maker could bring three more products to market over the next few years that could lead to increased adoption.



Current indications conservatively show a market potential of close to 200,000 to 300,000 cases in the U.S., Denhoy said. A successful trial could add “another couple hundred thousand patients,” he said.

The next key catalyst for investors, outside of second-quarter results expected in late October, will be the highly-anticipated presentation of its 50-patient STEMI door-to-unloading safety and feasibility study in November.



— With assistance by Javon Thompson

(Updates with details on the pump in the sixth paragraph, shares in seventh paragraph.)

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10